Print this article

PRODUCT & SERVICES

schermata-2016-09-27-alle-10-36-56

 

Company name: Albemarle Corporation

Year of foundation: 1994
Predecessor Company, Ethyl Corporation, founded in 1921

Number of employees: 6,900

Headquarter Country: USA

Website: www.albemarle.com/FCS

Offered Services 

Analytical services

Chemical synthesis / Custom manufacturing

cGMP-compliant production

Intellectual property

Pilot manufacturing & scale up

Process development

Product characterization

Regulatory support

Safety testing

Stability Storage

 

Albemarle Corporation (NYSE: ALB), headquartered in Charlotte, NC, is a global specialty chemicals company with leading positions in lithium, bromine, refining catalysts and applied surface treatments. We power the potential of companies in many of the world’s largest and most critical industries, from energy and communications to aerospace and electronics.  Working side-by-side with our customers, we develop value-added, customized solutions that make them more competitive. Our solutions combine the finest technology and ingredients with the knowledge and know-how of our highly experienced and talented team of operators, scientists and engineers. Discovering and implementing new and better performance-based sustainable solutions is what motivates all of us. We think beyond business-as-usual to drive innovations that create lasting value. Albemarle employs approximately 6,900 people and serves customers in approximately 100 countries.

 

 

schermata-2016-09-27-alle-10-37-05

 

Company name: Apollo Scientific

Year of foundation: 1993 

Number of employees: 81

Headquarter Country: UK

Website: www.apolloscientific.co.uk

Offered Services 

Chemical synthesis / Custom manufacturing

 

Apollo laboratories were built to support the catalogue operations of the company in terms of new product development and supply. We concentrate our efforts in two main areas: a) Fluorination technology – including nucleophilic fluorination, electrophilic fluorination, transition metal catalysed fluorination as well as fluorination using difluorocarbene technology; b) Downstream derivatisation of the fluorinated moieties leading to the formation of potential key intermediates for the Pharmaceutical and Agrochemical industry. To this end emphasis is placed on the synthesis of multi-functionality into the molecules leading to the formation of novel heterocyclic intermediates. Examples include the production of phenylenediamines, aminophenols, aminobenzonitriles, anthranilic acids, phthalic acids, catechols, salicylic acids, hydroxyacetophenones, methylanilines, and so on. Furthermore in order that the proposed heterocyclic system can be further derivatised then every attempt is made to introduce addition halogenation into the key intermediate thus forming highly halogenated heterocyclic scaffolds, which can be further derivatised to form novel systems.

Finally the laboratories through Apollo Scientific, its sister companies Synquest, Central Glass Germany, and the parent company Central Glass are ideally situated to develop such components from catalogue to commercial scale, through to GMP production, initially as in-house production thus offering the prospective client a smooth transition to scale up.

 

 

schermata-2016-09-27-alle-10-37-22

 

Company name: CEPiA - SANOFI

Year of foundation: 2008

Number of employees: Non applicable

Headquarter Country: France

Website: www.cepia-sanofi.com

Offered Services 

Chemical synthesis / Custom manufacturing

High potency compounds management

Packaging

Pharmaceutical formulations

Pre-Formulation & Formulation

Powder handling

Process development

Product characterization

 

Sanofi is one of the top five pharmaceutical companies in the world and a leader in pharmaceutical sciences. Sanofi excellence in pharmaceutical sciences is based on its experience with industrial development of all kinds of projects and bringing new chemical entities to market. The industrial organization within Sanofi known as Industrial Affairs includes a business unit dedicated to third-party activity named CEPiA (Commercial & External Partnership, Industrial Affairs). One of CEPiA’s missions as a Contract Manufacturing Organization is to provide its Customers manufacturing solutions supported by a dedicated team and close to their needs. 

Our high level of expertise has been acquired for many years and is based on five major principles: Extensive knowledge in Chemistry, Biochemistry and Biotechnology; State of the art facilities; Environment, Health and Safety experts; High standards in Quality and Regulatory; Dedicated teams with a strong Industrial Culture. 

CEPiA’S expertize again recognized, for the third year in a row, as the world CMO Leader in 2016, in five categories: QUALITY, RELIABILITY, CAPABILITIES, EXPERTISE AND COMPATIBILITY. This award confirms that these five categories are central to the FOCUS and are an integral part of CEPiA’s corporate culture, in addition to its ability to adapt to the requirements of an ever moving pharmaceutical world.

 

 

schermata-2016-09-27-alle-10-37-33

 

Company name: CordenPharma

Year of foundation: 2006 

Number of employees: 1600

Headquarter Country: Germany

Website: www.cordenpharma.com

Offered Services 

Analytical services

Chemical synthesis / Custom manufacturing

cGMP-compliant production

Drug development

High potency compounds management

Logistics and distribution

Pharmaceutical formulations

Pre-Formulation & Formulation

Powder handling

Process development

Product characterization

Regulatory support

Safety testing

 

CordenPharma is your full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Drug Products and associated Packaging Services. Through a network of fully-inspected cGMP facilities across Europe and the US organized under five technology platforms – Peptides, Lipids & Carbohydrates, Injectables, Highly Potent & Oncology, Small Molecules, Antibiotics - CordenPharma experts translate complex ideas at any stage of development into high-value products.  

Peptides, Lipids & Carbohydrates: Peptide API Production (Solid-phase, Liquid-phase, Hybrid Synthesis; cGMP & non-cGMP), Lipids, Carbohydrates.

Sterile Injectables: Sterile Drug Products, Packaging & Labeling, Sterile Emulsion Technology, Parenterals, Large Pre-Filled Syringes, Clinical Trial Services.

Highly Potent & Oncology: API Development & Commercial Manufacturing 

(SafeBridge Category 4, OEL ≤1 ng/m3), Drug Product Development & Manufacturing (Oral Solid Dosage Forms, Sterile Liquid & Lyofilistion, Primary & Secondary Packaging).

Small Molecules: Development & Commercial Manufacturing (Intermediates, APIs & Excipients, Clinical Supply from Phase I – III), Proprietary & Generic Advanced Intermediates & APIs.

Antibiotics: Non-segregated (Oral APIs, Oral & Sterile Drug Products, Primary & Secondary Packaging) Segregated (Cephalosporins & Penicillins, Monobactams, Primary & Secondary Packaging).

 

 

schermata-2016-09-27-alle-10-37-38

 

Company name: Evonik Industries AG

Year of foundation: 1843

Number of employees: Approx. 34000

Headquarter Country: Germany

Website: www.evonik.com

Offered Services 

Chemical synthesis / Custom manufacturing

Pilot manufacturing & scale up 

 

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik’s customers benefit specifically from its innovative and integrated technology platforms. 

The resource efficiency megatrend is well represented by the Catalysts Business Line which has been at the forefront of chemical catalysts for over 75 years, bringing catalyst ideas to life and creating value for its customers with its passion and focus. 

The Life Sciences & Fine Chemicals segment is one of three main markets for the Catalysts Business Line. Our precious metal catalysts produced under the Noblyst® brand and our Raney type nickel catalysts are ideally suited for the synthesis of pharmaceuticals, agro chemicals, and fine chemicals. With production and R&D facilities all over the world including India and China, we can offer customers in these applications higher flexibility and customized solutions wherever their products are being made.

 

 

schermata-2016-09-27-alle-10-37-38

 

Company name: Evonik Industries AG

Year of foundation: 2007 (former Degussa) 

Number of employees: Approx. 33500

Headquarter Country: Germany

Website:
www.evonik.com/exclusive-synthesis

Offered Services 

Analytical services

Chemical synthesis / Custom manufacturing

cGMP-compliant production

Drug delivery systems

High potency compounds management

Medical devices

Pilot manufacturing & scale up

Process development

Safety testing

 

Technically complex challenges are our core competence. With more than 200 employees in our R&D group we can tackle the most demanding technical challenges for our customers. Besides the classical organic chemistry we focus especially on continuous processes, fermentations, enzyme chemistry, catalysis, and high potency API (HPAPI). Evonik’s production network offers the world’s largest HPAPI capacity ranging from lab scale to 8.000 L reactors at OEL containment levels down to 0.1 microgram/m3. With more than 50 years of experience in continuous processing at Evonik, we offer a unique technical Know-How. 2/3 of all Evonik products are manufactured using various types of continuous processes. The combination of in-house catalyst design and production with best in class process development heritage offers tailored solutions to our customer’s process challenges. The same applies for Evonik’s biocatalysis and enzyme chemistry setup. From isolated enzymes to whole cell processes, from directed evolution to large-scale production we offer a holistic process development that does not only focus on one part of the chemical process. To offer an optimal service to our customers we constantly expand our technical capabilities. 

This includes several investments since 2014: Fermentation (upgrade of lab and strain development capabilities, installation of a multipurpose fermentation pilot plant), HPAPI (installation of a GMP HPAPI lab with OEL down to 5 ng/m3, constant upgrades to our production plants), API conjugation (set up of a conjugation lab). 

A new high-quality mPEG pilot plant is currently under construction.

 

 

schermata-2016-09-27-alle-10-38-23

 

Company name: Fermion Oy

Year of foundation: 1970 

Number of employees: 330

Headquarter Country: Finland

Website: www.fermion.fi

Offered Services 

Analytical services

Chemical synthesis / Custom manufacturing

cGMP-compliant production

High potency compounds management

Logistics and distribution

Pilot manufacturing & scale up

Powder handling

Process development

Product characterization

Regulatory support

Safety testing

Stability Storage

 

Fermion is a Finnish manufacturer of Active Pharmaceutical Ingredients (API) for both generic and proprietary drug products since 1970. We offer contract development and manufacturing solutions for APIs including oncology and HPAPIs up to the level of 0,1 µg/m3 containment. Our production capacity in both standard APIs and HPAPIs ranges from grams to tons. Fermion’s R&D expertise lies in process optimization, particle engineering and smart product lifecycle management. We have been approved by the FDA since 1979. 

 

“Do it once, do it right” is our philosophy in everything that we do. Benefits of choosing Fermion as a contract development and manufacturing partner include: One-stop-shop shortening time to market; Full scale of API production, no tech transfer costs; Security of supply; Your brand image stays spotless; Peace of mind. 

 

We offer a unique customer experience by functioning as an extension of your R&D, thinking like you. We take ownership of your projects and always keep a problem-solving attitude . We are proud of our transparent communication style and we respond quickly to your needs.

 

 

schermata-2016-09-27-alle-10-38-27

 

Company name: Grifols

Year of foundation: 1940 

Number of employees: 14000

Headquarter Country: Spain

Website: www.grifols.com
www.partnership.grifols.com

Offered Services 

cGMP-compliant production

Drug development

Packaging

Pharmaceutical formulations

Pilot manufacturing & scale up

Pre-Formulation & Formulation

Process development

Regulatory support

 

Grifols is a global healthcare company with a 75-year legacy of life-saving plasma medicines, hospital pharmacy products and diagnostic technology for clinical use. The company is present in more than 100 countries worldwide and its headquarters are located in Barcelona, Spain.

Grifols Partnership is the  business to business contract development and manufacturing platform for  sterile solutions and lipid emulsions with over 75 years’ experience in producing intravenous solutions for the pharmaceutical industry worldwide.

Over the years we have established successful relationships with customers in global markets, including North America, Canada, Australia and Europe in the following areas: Human & Veterinary fields, New product development, Generic drugs.

Grifols Partnership has two FDA and GMP approved manufacturing facilities in Spain for intravenous solutions that have parametric release certification.

Grifols Partnership works together with the customer from the early stages of development until commercial manufacturing.

Container Technologies: Flexible Polypropylene IV Bags, Glass vials.

 

 

schermata-2016-09-27-alle-10-38-39

 

Company name: Indena S.p.A.

Year of foundation: 1921 

Number of employees: more than 800

Headquarter Country: Italy

Website: www.indena.com

Offered Services 

Analytical services

Chemical synthesis / Custom manufacturing

cGMP-compliant production

High potency compounds management

Pilot manufacturing & scale up

Pre-Formulation & Formulation

Process development

Product characterization

Regulatory support

Stability Storage

 

Indena is an Italian company specialized in isolation, extraction, purification, development and bulk-manufacturing of active principles from botanical sources for the pharma and health-food industry.

Indena is very well known as the world leading supplier of anticancer drugs of the taxanes family and natural/semisynthetic APIs, HPAIs and highly standardized botanical extracts.

Today Indena opens its facilities for custom services, sharing with customers its innovative research and production capabilities at lab, kilo-lab and industrial scale.

The Phytosome® technology, specifically developed by the company to optimize the performance of botanical extracts, represents an added value for pharma companies wishing to produce drugs starting from botanical sources.

More than ninety years of Indena expertise in handling of botanicals and of presence in the pharmaceutical market are a guarantee of high quality standards and reliability (compliance with the highest quality standards and international regulations), values very appreciated by our customers.

 

 

schermata-2016-09-27-alle-10-38-57

 

Company name: Johnson Matthey

Year of foundation: 1817

Number of employees: 13000

Headquarter Country: UK

Website: www.jmfinechemicals.com

Offered Services 

Chemical synthesis / Custom manufacturing

cGMP-compliant production

Drug development

Drug discovery

High potency compounds management

Pilot manufacturing & scale up

Preclinical research

Pre-Formulation & Formulation

Process development

Product characterization

Regulatory support

Stability Storage

 

Johnson Matthey Fine Chemicals provides high quality, value-adding products and services through its four core offerings: Custom Pharma Solutions, Controlled Substances, APIs & Life Cycle Management and Catalysts, ensuring your complex chemistry problems are solved. 

The Custom Pharma Solutions offering is tailored to you and provides a full range of dedicated drug development, scale-up and manufacturing services, through pre-clinical and toxicological studies to development and commercial manufacturing. Its services includes: API process development and manufacture, high potency API capabilities, drug conjugates and linkers, catalytic process screening, biocatalysis and the newly acquired Pharmorphix® solid form sciences. 

Johnson Matthey Fine Chemicals’ world-leading services enable new possibilities and cutting-edge advances for your pharmaceutical and chemical products. The company’s expertise and experience in developing and optimising synthetic processes, discovering the most efficient, sustainable routes and scaling up intermediates ensures products get to market faster. As well as this, Johnson Matthey Fine Chemicals has expertise in high potency handling, controlled substance management and separation technologies. Its global facilities include kilo-laboratories, pilot plant and commercial scale assets, allowing Johnson Matthey to handle the most complex chemistries, including speciality chemical development and a wide range of process conditions whilst adhering to environmental and process safety best practices.

 

 

schermata-2016-09-27-alle-10-39-03

 

Company name: Micro-Macinazione SA

Year of foundation: 1970 

Number of employees: 115

Headquarter Country: Switzerland

Website: www.micromacinazione.com

Offered Services 

Analytical services

Custom manufacturing (micronization and milling)

cGMP-compliant production

High potency compounds management

Pilot manufacturing & scale up

Powder handling (micronization and milling)

 

Contract micronization and milling.

With over 45 years of experience, swiss-based Micro-Macinazione S.A. is the most competent provider of Micronization services and equipment for the Pharmaceutical & Fine Chemical industry. 

The company is situated on 3 sites, two of them cGMP compliant, dedicated to the micronization service, are regularly inspected by FDA, Swiss Medic and certified by Japanese Health Authorities. The two production sites are equipped with 28 jet mills, 2 pin mills, glove boxes and pneumatic conveyors contributing to the highest micronization capacity in Europe of over 1’000 tons/year. In the third site, the Engineering division is dedicated to the supply of standard or fully customized equipment to meet worldwide customers’ needs as well as development of equipment used within our micronization division. 

Micro-Macinazione is uniquely positioned as an expert in both micronization and engineering. The synergy between these competencies and the R&D division in its new testing and developing center enables us to develop process solutions for micronizing API and HAPIs and new innovative technologies for solubility improvement of poorly soluble drugs. 

 

 

schermata-2016-09-27-alle-10-39-16

 

Company name: Minakem High Potent

Year of foundation: 1972 site started operations, since 2015 as new business unit within Minafin Group

Number of employees: 100

Headquarter Country: Belgium

Website: www.minakem-high-potent.com

Offered Services 

Chemical synthesis / Custom manufacturing

cGMP-compliant production

High potency compounds 

Pilot manufacturing & scale up

Process development

Product characterization

Regulatory support

Safety testing

Stability Storage

 

Minakem High Potent is a recognized world leader custom manufacturer for development and commercialization of Highly Potent APIs (HAPIs) requiring production under high containment systems down to OEB class 5 (OEL < 0.1μg per m3 per 8 hour shift).

The site has more than 40 years of experience in serving global pharmaceutical companies in handling HAPI and cytotoxic compounds as well as controlled substances from process and analytical development within our R&D labs, scale-up and production, with manufacturing setting and capacity from grams to hundred kgs following customer requirements.

Minakem High Potent is a full GMP compliant and FDA inspected production site (8 successful inspections since 1983, latest in September 2015) that can also provide full regulatory support including the filing of regulatory dossiers with the health authorities (DMF, CEP).

 

 

schermata-2016-09-27-alle-10-39-21

 

Company name: Navin Fluorine International Limited

Year of foundation: 1967 

Number of employees: 650

Headquarter Country: India

Website: www.nfil.in 

www.manchesterorganics.com

Offered Services 

Chemical synthesis / Custom manufacturing

cGMP-compliant production

Drug development

Drug discovery

Pilot manufacturing & scale up

Preclinical research

Powder handling

Process development

Safety testing

Stability Storage

 

Selective insertion of fluorine, either as a single fluoride or as part of more complex functional group has long been a desirable technology in both the biopharmaceuticals and agrochemicals sectors. 

Traditional reagents for introducing a fluorine moiety are typically hazardous and difficult to handle and many new fluorination reagents have been developed in recent years which aim to minimise these hazards. However, these reagents often come with considerable barriers to use at commercial scales, whether it be their cost or relatively high molecular weight. 

Direct fluorination with SF4 offers many advantages over more complex fluorination reagents in that it is relatively atom-efficient and much lower in cost. However, SF4 remains an extremely hazardous reagent to handle and use. 

Based out of India & the UK, Navin Fluorine has an extensive track-record of successfully producing and developing a diverse range of organo-fluorine compounds using SF4. 

As one of the premier providers of fluorination technology, we routinely carry out complex multi-stage custom synthesis where high pressure fluorination is integral to the chemistry. Not only this, we can support our clients from gram to tonne scale and to full cGMP if necessary.

 

 

schermata-2016-09-27-alle-10-39-28

 

Company name: Olon S.p.A.

Year of foundation: 1907 

Number of employees: 800

Headquarter Country: Italy

Website: www.olonspa.com

Offered Services 

Chemical synthesis / Custom manufacturing

cGMP-compliant production

High potency compounds management

Pilot manufacturing & scale up

Regulatory support

 

Olon SpA is one of the world leading producers of APIs with 5 production plants located in Italy. 

HPAPI: In its high containment laboratories and plants Olon has developed and produced a wide range of  anticancer compounds thanks to its proper equipments for the handling of chemicals highly toxic for the workers and for the  environment.

Biotechnology R&D: Strong skills in biotechnology area; R&D for high-value products (proteins, hormones, antibody); Technological competitiveness based on expertise  in microbial and mammalian fermentation processes; Equipments to scaling-up microbial fermentation and recovery of biological substances; Preparation of Master Cell Bank / Working Cell Bank; Strain selection and improvement (Genetic engineering, Mutagenesis, Genome shuffling).

Fermentation: Availing itself of 3100 m3 of fermentation capacity, with this technology Olon is in a position to  produce also molecules that may require high containment already during fermentation, with annual  volumes ranging from the few kilograms up to hundreds of tons, obtained directly via fermentation  or from fermentation derived building blocks.

Synthetic organic chemistry: In the area of fully synthetic organic chemicals, Olon has a wide range of advanced and sophisticated  technologies that consent to obtain very complex APIs and building blocks.

 

 

schermata-2016-09-27-alle-10-39-37

 

Company name: PharmaZell GmbH

Year of foundation: 1947 

Number of employees: 800

Headquarter Country: Germany

Website: www.pharmazell.com 

Offered Services 

Analytical services

Chemical synthesis / Custom manufacturing

cGMP-compliant production

Drug development

High potency compounds management

Pharmaceutical formulations

Pilot manufacturing & scale up

Pre-Formulation & Formulation

Process development

Product characterization

Regulatory support

Safety testing

Stability Storage

 

PharmaZell is a German based, technology-focused manufacturer of active pharmaceutical ingredients. 

The PharmaZell Group operates five cGMP sites in Europe and Asia. Founded in 1947 we are looking on a long history of serving the pharmaceutical industry with products and services. For all development stages we offer tailor made solutions in process development and process optimization combined with up-to-date technology, analytics and experience in a wide field of chemical conversions. 

Our services comprise the synthesis and manufacturing of the API and the development of solid oral dosage forms. Regulatory supports for API or FDF are provided. Small molecule custom synthesis at PharmaZell starts at the early stages of pre-clinical development; moreover, PharmaZell`s custom manufacturing is able to manufacture your API in large scale to meet your future commercial needs. 

Our facilities are regularly inspected by all important regulatory authorities. 

Our overall portfolio includes more than 100 APIs; beneath generic APIs we offer Highly Potent- and Anticancer-Cytotoxic Substances as well as Amino Acids.

 

 

 

schermata-2016-09-27-alle-10-39-42

 

Company name: Piramal Pharma Solutions

Year of foundation: 2003

Number of employees: over 4000

Headquarter Country: India

Website: www.piramalpharmasolutions.com 

Offered Services 

Analytical services

Chemical synthesis / Custom manufacturing

cGMP-compliant production

Drug development

Drug discovery

High potency compounds management

Packaging

Pharmaceutical formulations

Pilot manufacturing & scale up

Pre-Formulation & Formulation

Process development

Product characterization

Regulatory support

Stability Storage

 

Piramal Pharma Solutions is a contract development and manufacturing organization (CDMO), offering end-to-end pharmaceutical development and manufacturing solutions throughout the drug life cycle. We have created a vast network of development and manufacturing facilities located in North America, Europe and Asia that offers a multitude of services covering the entire drug life cycle, from Drug Discovery and Development to Commercial Manufacturing of off-patent APIs and Finished Dosage Forms. Our capability as an integrated service provider and experience with various technologies enables us to serve Innovator and Generic companies worldwide. Our Development centers and Manufacturing sites have accreditations from regulatory bodies in US, Europe & Japan. With a pool of 450 scientists, including 100 Ph.d’s across the Globe we are committed to Research & Development programs. We offer specialized services such as Antibody Drug Conjugation and are well versed in technologies such as Bio-catalysis. At Piramal Solutions, we are moving towards becoming a ‘Customer Centric’ organization by focusing on the “Pulse of the Customer”. 

 

 

 

schermata-2016-09-27-alle-10-39-48

 

Company name: PolyPeptide Group

Year of foundation: 1996

Number of employees: 500

Headquarter Country: Sweden

Website: www.polyPeptide.com

Offered Services 

Chemical synthesis / Custom manufacturing:  Manufacturing of pre-clinical peptides

cGMP-compliant production: Manufacturing of clinical grade peptides as applied to Phase I-III clinical trials and commercial application

 

The PolyPeptide Group is a privately-held group who focuses on manufacturing of proprietary and generic GMP-grade peptides for the pharmaceutical and biotechnological market. 

With more than 50 years of experience, the Group is committed to the highest quality of peptide manufacturing, irrespective of whether this is for approved drug substances, GMP peptides in clinical trials, or small-scale non-GMP custom syntheses.

 

 

schermata-2016-09-27-alle-10-39-54

 

Company name: Siegfried AG

Year of foundation: 1873

Number of employees: 2238 

Headquarter Country: Switzerland

Website: www.siegfried.ch

Offered Services

Analytical services 

Chemical synthesis /
Custom manufacturing 

cGMP-compliant production

Drug delivery systems 

Drug development

High potency compounds
management 

Intellectual property 

Logistics and packaging

Mixing processes 

Packaging 

Pharmaceutical formulations 

Pilot manufacturing & scale up

Pre-Formulation & Formulation 

Process development 

Product characterization 

Regulatory support 

Stability Storage

 

Siegfried is your preferred partner for complete integrated drug substance and drug product services with production capabilities worldwide. Our professionalism is pivotal for your project throughout the entire life cycle. Creating and manufacturing formulations is our passion. Having such a combination of inherited technical know-how and expertise is unique for a supplier of development and manufacturing services. Drug Substances services include Custom Development and Contract Manufacturing for both API and intermediates, combined with our own product portfolio of API (opiates and other controlled substances) and dossiers with independent patented technologies. Drug Products clients benefit from a broad base of inherited knowledge in complex oral drug delivery systems including sterile filling, with in-house development, customer development and manufacturing, and a broad portfolio of finished dosage form products. Improving chemical processes and formulations is our expertise. We work closely with customers to develop and optimize innovative chemical processes adding more benefit and value. Siegfried has nine sites worldwide spanning both the Eastern and Western Hemispheres with chemical manufacturing multi-purpose cGMP locations in Zofingen, Switzerland; Pennsville, New Jersey (USA); Nantong, China; Minden, Germany; Saint-Vulbas, France; Evionnaz, Switzerland; and drug product manufacturing sites in Zofingen, Switzerland (Pilot); Malta; Hameln, Germany, and Irvine, USA. Expect more with Siegfried as your preferred partner.

 

 

schermata-2016-09-27-alle-10-39-59

 

Company name: SiliCycle Inc.

Year of foundation: Incorporated in 1995 

Headquarter Country: Canada

Website: www.silicycle.com

Offered Services 

Analytical services

Chemical synthesis / Custom manufacturing

Consulting

Drug development

Drug discovery

Pilot manufacturing & scale up

Powder handling

Process development

Product characterization

Regulatory support

 

For over 20 years, SiliCycle has been dedicated to the development of silica-based products and has acquired extensive experience in grafting technology, where useful organic functionalities are immobilized onto an inorganic support. These functionalized silicas can then be optimized for specific applications such as scavenging different metals and/or organic residues from a reaction mixture.

This grafted technology enables stronger, faster purifications than classical processes to achieve new purity standards. Immobilisation is an elegant, clean and practical strategy to scavenge any metallic or organic impurity you might be bothered with. Just filter-off the heterogeneous scavenger bounded to the trapped molecule to achieve an impurity-free solution.

Our solutions are extremely versatile (pH, solvents, temperatures) and customizable, and have thus become a routine and fashionable purification strategy suitable for a vast array of industries, facing different contamination issues.

Discover what the scavenging technology from SiliCycle has to offer and how it can assist you in these times of environmental changes and tighter quality controls.

SiliCycle is also a leading service provider, offering turnkey solutions based on its long expertise in organic chemistry, catalysis, extraction, purification and analytical chemistry.

 

 

schermata-2016-09-27-alle-10-40-05

 

Company name: Wychem Limited

Year of foundation: 1968 

Number of employees: 27

Headquarter Country: UK

Website: www.wychem.com

Offered Services 

Chemical synthesis / Custom manufacturing

GMP expected  status for registered start materials

 

Established in 1968, WYCHEM has grown to become an important source of speciality and fine chemicals. Our success has been achieved though continuous improvement in the quality of our products, operations and competitiveness with strict observance to health, safety and environmental compliance.

Our principle product markets include pharmaceutical, personal care and electronics and all are characterised by highly exacting quality requirements for consistency and reproducibility.

Our technology platform is centred upon halogenation, most commonly but not restricted to bromination, chlorination and iodination via Diazonium and Sandmeyer reactions and experienced expertise for handling such hazardous reagents to enable an offer of a full range of functional groups: 

Acids, esters, aldehydes, acetals ,ketones, phenols, anisoles, alkyloxy compounds & phenylacetates, alcohols, nitriles, anilines, amides, amines and nitro compounds.

WYCHEM’s ethos is to be responsive to customer needs and to create added value. An immediate response to enquiries and focused agility in scale up from grams to multi-tons is achieved by lean decision processes and an experienced and highly skilled workforce.